Due Diligence Valeant said last month that it "has conducted extensive due diligence" and will be able to quickly work down excess drug inventory that Salix built up. Endo's outside spokesman Aaron Palash declined to comment on the matter. Salix agreed Monday to Valeant's raised offer of $173 per share in cash, or $11.1 billion, beating out Endo's offer of $175 a share in cash and stock. Salix shares rose 2 percent to $172.80 at 1:27 p.m. in New York, close to an all-time high. Salix's stock fell 34 percent on Nov. 7 after the accounting problems were revealed. While that now looks like a forgotten bad dream, the drugmaker's restated filings this month show the veritable buffet of accounting errors that led to that decline. Product Rebates Salix said that in July 2014, it paid one of its distributors $7.5 million for "marketing services," and counted the cost toward expenses.